Plant Name: Dendrosenecio kilimanjari
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; FFAR1; FFAR4; | |
| TSHR; OPRD1; | |
| FAAH; TDP1; TERT; HPGD; ALOX15; ALDH1A1; USP2; UBE2N; | |
| TRPA1; | |
| MAPK1; | |
| CA12; CA13; CA1; CA9; CA7; | |
| PPARA; PPARD; PPARG; | |
| THRB; | |
| NR1I2; | |
| PTGS1; | |
| TLR2; | |
| HIF1A; | |
| ABCB1; ABCG2; | |
| SLCO1B1; SLCO1B3; | |
| NPC1; RAB9A; LMNA; FABP3; FABP5; FABP4; MAPT; FABP2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | UBE2N | Ubiquitin-conjugating enzyme E2 N | P61088 | CHEMBL6089 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.123E-10 | 4.074E-07 | CA1, CA12, CA13, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.363E-08 | 1.855E-05 | CA1, CA12, CA13, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.876E-08 | 4.964E-05 | CA1, CA12, CA13, CA7, CA9 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 6.751E-08 | 7.350E-05 | NR1I2, PPARA, PPARD, PPARG, THRB |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 1.744E-07 | 1.552E-04 | NR1I2, PPARA, PPARD, PPARG, THRB |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.362E-07 | 1.774E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 6.502E-07 | 3.726E-04 | ABCB1, ABCG2, FABP3, NPC1, SLCO1B1, SLCO1B3 |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 1.135E-06 | 5.884E-04 | ABCB1, ABCG2, NR1I2 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 1.911E-06 | 8.160E-04 | HIF1A, MAPK1, MAPT, NPC1, OPRD1, PPARA, THRB, TLR2, USP2 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.031E-06 | 8.506E-04 | NR1I2, PPARA, PPARD, PPARG, THRB, UBE2N |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.982E-06 | 1.142E-03 | HIF1A, LMNA, OPRD1, PPARD, TERT |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 4.890E-06 | 1.690E-03 | CYP19A1, FFAR4, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.132E-06 | 2.389E-03 | CA1, CA12, CA13, CA7, CA9, NR1I2, PPARA, PPARD, PPARG, THRB |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 8.904E-06 | 2.938E-03 | NR1I2, PPARA, PPARD, PPARG, THRB |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 1.180E-05 | 3.671E-03 | ALDH1A1, CYP19A1, CYP3A4, FFAR1, FFAR4, HIF1A, PPARD, SLCO1B1 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 1.340E-05 | 3.997E-03 | FABP3, PPARA, PPARD, PPARG |
| MF | Unclassified; | GO:0004872; receptor activity | 1.575E-05 | 4.571E-03 | ADORA3, FFAR1, FFAR4, HPGD, NPC1, NR1I2, OPRD1, PPARA, PPARD, PPARG, THRB, TLR2, TSHR |
| MF | GO:0005488; binding | GO:0043167; ion binding | 1.706E-05 | 4.823E-03 | ABCB1, ABCG2, ALOX15, CA1, CA12, CA13, CA7, CA9, CYP19A1, CYP3A4, FABP2, FABP3, FABP4, FABP5, FFAR4, HPGD, MAPK1, NR1I2, PPARA, PPARD, PPARG, PTGS1, RAB9A, TERT, THRB, UBE2N, USP2 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 2.432E-05 | 6.306E-03 | NR1I2, PPARA, PPARD, PPARG, THRB |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 2.709E-05 | 6.939E-03 | FABP3, FFAR1, PPARG, TLR2 |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 2.788E-05 | 7.011E-03 | ALDH1A1, ALOX15, CYP19A1, CYP3A4, HIF1A, NPC1, PPARD |
| BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 3.015E-05 | 7.461E-03 | FABP3, PPARA, PPARG |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.043E-10 | 1.260E-08 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.939E-10 | 1.260E-08 | CA12; CA1; CA7; CA9; CA13 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.753E-07 | 1.626E-05 | SLCO1B1; ABCB1; SLCO1B3; CYP3A4; ABCG2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.209E-04 | 7.180E-03 | FABP4; TSHR; PTGS1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.674E-03 | 2.945E-02 | ALOX15; MAPK1; PTGS1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.943E-03 | 2.945E-02 | THRB; MAPK1; HIF1A |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.665E-03 | 3.464E-02 | OPRD1; THRB; ADORA3; TSHR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.039E-03 | 2.945E-02 | OPRD1; ADORA3; MAPK1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.686E-03 | 2.945E-02 | MAPK1; PPARG |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.686E-03 | 2.945E-02 | ALOX15; CYP3A4 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 3.851E-03 | 4.552E-02 | ABCB1; ABCG2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; TERT |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TERT |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH; PTGS1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; PPARG; PPARG |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1; TERT |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; TERT |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRD1; TRPA1; FAAH; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; CYP3A4; FAAH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; HIF1A; CA9; MAPK1; TLR2 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; FAAH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; NR1I2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ABCB1; ADORA3; HIF1A; CA1; CA9; MAPK1; TLR2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; CA1; CA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |